SELECTIVE ELIMINATION OF EROSIVE CELLS

The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-NKG2A antibody. La présente inv...

Full description

Saved in:
Bibliographic Details
Main Authors GALSGAARD, ELISABETH DOUGLAS, SOEDERSTROEM, KALLE
Format Patent
LanguageEnglish
French
Published 20.12.2012
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-NKG2A antibody. La présente invention concerne le traitement de maladies caractérisées par la destruction du cartilage et/ou l'érosion osseuse. L'invention se rapporte en particulier au traitement de l'ostéoarthrite, de l'ostéoporose, de l'arthrite psoriasique ou de l'arthrite rhumatismale par un anticorps anti-NKG2A.
Bibliography:Application Number: WO2012EP61583